Christian Salib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian Salib has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Samir Parekh
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
12 shared publications - Sundar Jagannath
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
12 shared publications - Adolfo Aleman
Icahn School of Medicine at Mount Sinai, New York, New York, United States
11 shared publications - Adriana Rossi
Icahn School of Medicine at Mount Sinai, New York, NY
11 shared publications - Cesar Rodriguez
Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
11 shared publications - Darren Pan
Division of Hematology/Oncology University of California San Francisco San Francisco California USA
11 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Data from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Purpose:Chimeric antigen receptor T cells (CAR-T) have demonstrated remarkable efficacy in multiple myeloma, but prolonged hematologic toxicity remains a common adverse event, and secondary myeloid malignancies are a significant safety concern.Experimental Design:We evaluated 213 patients with myeloma treated with B-cell maturation antigen–directed CAR-T at our center to characterize clinical, inflammatory, and myeloid clonal features associated with hematologic toxicity.Results:Patients with persistent grade ≥3 neutropenia or thrombocytopenia at day 100 (19%) had shorter progression-free survival (P = 0.0003) and overall survival (P < 0.0001), and among those with continued remissions, 64% developed prolonged high-grade cytopenias beyond 1 year. Whereas baseline inflammation is a risk factor for hematologic toxicity, underlying clonal hematopoiesis (CH) modulated this risk, and the combination of CH and elevated ferritin was highly predictive of delayed recovery (adjusted HR, 0.38, P = 0.006). Serum cytokine analysis in patients with delayed myeloid recovery showed a signature of persistent inflammation and endothelial dysfunction. Finally, 9% developed secondary myeloid diseases, including 5% with high-grade myelodysplastic syndrome (MDS) requiring therapy, a median of 14.5 months after CAR-T. MDS was associated with clonal expansion of underlying TP53-mutated CH from a median variant allele frequency of 3.4% before CAR-T to 44.0%. Whereas patients with baseline TP53-mutated CH exhibited clonal evolution and a high incidence of MDS (67%), other CH mutations did not show similar expansion after CAR-T (P > 0.99).Conclusions:This study underscores the impact of hematologic toxicity and CH on B-cell maturation antigen CAR-T outcomes and suggests a potential role of CAR-T in influencing TP53 clonal dynamics and myeloid disease development.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Purpose:Chimeric antigen receptor T cells (CAR-T) have demonstrated remarkable efficacy in multiple myeloma, but prolonged hematologic toxicity remains a common adverse event, and secondary myeloid malignancies are a significant safety concern.Experimental Design:We evaluated 213 patients with myeloma treated with B-cell maturation antigen–directed CAR-T at our center to characterize clinical, inflammatory, and myeloid clonal features associated with hematologic toxicity.Results:Patients with persistent grade ≥3 neutropenia or thrombocytopenia at day 100 (19%) had shorter progression-free survival (P = 0.0003) and overall survival (P < 0.0001), and among those with continued remissions, 64% developed prolonged high-grade cytopenias beyond 1 year. Whereas baseline inflammation is a risk factor for hematologic toxicity, underlying clonal hematopoiesis (CH) modulated this risk, and the combination of CH and elevated ferritin was highly predictive of delayed recovery (adjusted HR, 0.38, P = 0.006). Serum cytokine analysis in patients with delayed myeloid recovery showed a signature of persistent inflammation and endothelial dysfunction. Finally, 9% developed secondary myeloid diseases, including 5% with high-grade myelodysplastic syndrome (MDS) requiring therapy, a median of 14.5 months after CAR-T. MDS was associated with clonal expansion of underlying TP53-mutated CH from a median variant allele frequency of 3.4% before CAR-T to 44.0%. Whereas patients with baseline TP53-mutated CH exhibited clonal evolution and a high incidence of MDS (67%), other CH mutations did not show similar expansion after CAR-T (P > 0.99).Conclusions:This study underscores the impact of hematologic toxicity and CH on B-cell maturation antigen CAR-T outcomes and suggests a potential role of CAR-T in influencing TP53 clonal dynamics and myeloid disease development.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S2: Prolonged hematologic toxicity at 1 year post-CAR-T for patients who remained MRD-negative, divided by initial myeloid recovery by day 100. Duffy-null individuals with isolated grade 2 neutropenia (n = 5) were excluded.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S2: Prolonged hematologic toxicity at 1 year post-CAR-T for patients who remained MRD-negative, divided by initial myeloid recovery by day 100. Duffy-null individuals with isolated grade 2 neutropenia (n = 5) were excluded.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S1. (A-B) Progression-free survival (PFS) (A) and overall survival (OS) (B) divided by myeloid recovery status at 30 days after CAR-T infusion, with estimated median survival times and hazard ratios (HR) with 95% confidence intervals (CI) for progression or death. NR, not reached.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S1. (A-B) Progression-free survival (PFS) (A) and overall survival (OS) (B) divided by myeloid recovery status at 30 days after CAR-T infusion, with estimated median survival times and hazard ratios (HR) with 95% confidence intervals (CI) for progression or death. NR, not reached.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S4: Extended data for the patients with secondary MDS/AML or CCUS
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S4: Extended data for the patients with secondary MDS/AML or CCUS
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S3. (A-B) Progression-free survival (A) and overall survival (B) stratified by baseline ferritin (ferr.) and clonal hematopoiesis (CH), with estimated median and/or 24-month survival and hazard ratios (HR) with 95% confidence intervals (CI) shown. NR, not reached.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S3. (A-B) Progression-free survival (A) and overall survival (B) stratified by baseline ferritin (ferr.) and clonal hematopoiesis (CH), with estimated median and/or 24-month survival and hazard ratios (HR) with 95% confidence intervals (CI) shown. NR, not reached.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S3: Patient demographics and recovery by baseline CH status
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S3: Patient demographics and recovery by baseline CH status
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S5. (A) Scatter plot of time to MDS/AML diagnosis after CAR-T versus prior lines of therapy, with best fitting line shown by linear regression.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S5. (A) Scatter plot of time to MDS/AML diagnosis after CAR-T versus prior lines of therapy, with best fitting line shown by linear regression.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S1: Full gene list used to define clonal hematopoiesis
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Table S1: Full gene list used to define clonal hematopoiesis
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S2. (A) Distribution of clonal hematopoiesis (CH) among the 90 patients with evaluable NGS, divided by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin at the time of CAR-T infusion. (B) CH patients by number of CH-associated mutations. (C-E) Time to sustained myeloid recovery stratified by pre-existing CH (C), by the 4 most common CH mutations (D), or by both baseline ferritin (ferr.) and CH (E), with medians and hazard ratio (HR) with 95% confidence intervals (CI) shown.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S2. (A) Distribution of clonal hematopoiesis (CH) among the 90 patients with evaluable NGS, divided by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin at the time of CAR-T infusion. (B) CH patients by number of CH-associated mutations. (C-E) Time to sustained myeloid recovery stratified by pre-existing CH (C), by the 4 most common CH mutations (D), or by both baseline ferritin (ferr.) and CH (E), with medians and hazard ratio (HR) with 95% confidence intervals (CI) shown.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S4. (A) Time to sustained myeloid recovery stratified by CH-R alone, with medians and hazard ratio (HR) with 95% confidence interval (CI) shown. (B) Time to sustained myeloid recovery, stratified by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin (ferr.) and by CH-R, with medians and adjusted hazard ratios (aHR) with 95% CI after multivariable model also including age, prior lines of therapy, and high-risk cytogenetic abnormalities. CH-R is clonal hematopoiesis restricted only to mutations in DNMT3A, TET2, ASXL1, or PPM1D.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy
Figure S4. (A) Time to sustained myeloid recovery stratified by CH-R alone, with medians and hazard ratio (HR) with 95% confidence interval (CI) shown. (B) Time to sustained myeloid recovery, stratified by low (<300 ng/mL) or high (≥300 ng/mL) baseline ferritin (ferr.) and by CH-R, with medians and adjusted hazard ratios (aHR) with 95% CI after multivariable model also including age, prior lines of therapy, and high-risk cytogenetic abnormalities. CH-R is clonal hematopoiesis restricted only to mutations in DNMT3A, TET2, ASXL1, or PPM1D.